Donaldson Capital Management buys $21,815,484 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Donaldson Capital Management scooped up 18,973 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 484,358 shares of Abbott Laboratories which is valued at $21,815,484.Abbott Laboratories makes up approximately 2.91% of Donaldson Capital Management’s portfolio.

Other Hedge Funds, Including , Wellington Shields boosted its stake in ABT in the latest quarter, The investment management firm added 29 additional shares and now holds a total of 22,732 shares of Abbott Laboratories which is valued at $1,023,849. Abbott Laboratories makes up approx 0.59% of Wellington Shields’s portfolio.Ropes Wealth Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 1,148 additional shares and now holds a total of 25,804 shares of Abbott Laboratories which is valued at $1,162,470. Abbott Laboratories makes up approx 0.40% of Ropes Wealth Advisors’s portfolio.Mutual Of America Capital Management reduced its stake in ABT by selling 30,117 shares or 14.97% in the most recent quarter. The Hedge Fund company now holds 171,011 shares of ABT which is valued at $7,686,944. Abbott Laboratories makes up approx 0.16% of Mutual Of America Capital Management’s portfolio.Chatham Capital Group boosted its stake in ABT in the latest quarter, The investment management firm added 754 additional shares and now holds a total of 73,224 shares of Abbott Laboratories which is valued at $3,276,774. Abbott Laboratories makes up approx 0.99% of Chatham Capital Group’s portfolio.

Abbott Laboratories opened for trading at $41.92 and hit $42.34 on the upside on Thursday, eventually ending the session at $42.3, with a gain of 0.67% or 0.28 points. The heightened volatility saw the trading volume jump to 1,07,39,240 shares. Company has a market cap of $62,181 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.